GIUSEPPE DI BELLA > NEWS > null > null > La Vitamina D nelle malattie linfoproliferative

 
La Vitamina D nelle malattie linfoproliferative di S.I.B.O.R. - M.D.B.
 
 
Data: 14/07/2006
Tipologia: MDB - Documentazione
Lingua: Italiano
Anno: 2006
 
 
Descrizione:

PER LEGGERE E SCARICARE IL CAPITOLO SULLA VITAMINA D, COMPLETO DI BIBLIOGRAFIA E RELATIVI ABSTRACT, CLICCARE QUESTO LINK.
Il file è di 48 pagine in formato PDF e pesa 217 kb.


BIBLIOGRAFIA





Abe-Hashimoto, J., T. Kikuchi, et al. (1993). "Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen." Cancer Res 53(11): 2534-7.





Abe, E., C. Miyaura, et al. (1981). "Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3." Proc Natl Acad Sci U S A 78(8): 4990-4.





Beer, T. M. and A. Myrthue (2004). "Calcitriol in cancer treatment: from the lab to the clinic." Mol Cancer Ther 3(3): 373-81.





Beno, D. W., L. M. Brady, et al. (1995). "Protein kinase C and mitogen-activated protein kinase are required for 1,25-dihydroxyvitamin D3-stimulated Egr induction." J Biol Chem 270(8): 3642-7.





Berger, U., P. Wilson, et al. (1988). "Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues." J Clin Endocrinol Metab 67(3): 607-13.





Bernardi, R. J., C. S. Johnson, et al. (2002). "Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells." Endocrinology 143(7): 2508-14.





Bernardi, R. J., D. L. Trump, et al. (2001). "Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling." Clin Cancer Res 7(12): 4164-73.





Calvo, M. S., S. J. Whiting, et al. (2005). "Vitamin D intake: a global perspective of current status." J Nutr 135(2): 310-6.





Celli, A., C. Treves, et al. (1999). "Vitamin D receptor in SH-SY5Y human neuroblastoma cells and effect of 1,25-dihydroxyvitamin D3 on cellular proliferation." Neurochem Int 34(2): 117-24.





Colston, K., M. J. Colston, et al. (1981). "1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture." Endocrinology 108(3): 1083-6.





Colston, K. W., S. K. Chander, et al. (1992). "Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro." Biochem Pharmacol 44(4): 693-702.





Consolini, R., S. Pala, et al. (2001). "Effects of vitamin D on the growth of normal and malignant B-cell progenitors." Clin Exp Immunol 126(2): 214-9.





Cross, H. S., C. Huber, et al. (1991). "Antiproliferative effect of 1,25-dihydroxyvitamin D3 and its analogs on human colon adenocarcinoma cells (CaCo-2): influence of extracellular calcium." Biochem Biophys Res Commun 179(1): 57-62.





Cunningham, D., N. L. Gilchrist, et al. (1985). "Alfacalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas." Br Med J (Clin Res Ed) 291(6503): 1153-5.





French, L. E., A. A. Ramelet, et al. (1994). "Remission of cutaneous T-cell lymphoma with combined calcitriol and acitretin." Lancet 344(8923): 686-7.





Fujioka, T., M. Hasegawa, et al. (1998). "Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma." J Urol 160(1): 247-51.





Guyton, K. Z., T. W. Kensler, et al. (2003). "Vitamin D and vitamin D analogs as cancer chemopreventive agents." Nutr Rev 61(7): 227-38.





Guzey, M., C. Sattler, et al. (1998). "Combinational effects of vitamin D3 and retinoic acid (all trans and 9 cis) on proliferation, differentiation, and programmed cell death in two small cell lung carcinoma cell lines." Biochem Biophys Res Commun 249(3): 735-44.





Hara, K., K. Kusuzaki, et al. (2001). "Oral administration of 1 alpha hydroxyvitamin D3 inhibits tumor growth and metastasis of a murine osteosarcoma model." Anticancer Res 21(1A): 321-4.





Hashimoto, E., H. Takeuchi, et al. (1989). "[1 alpha(OH) D3 (Alfarol) is effective for the treatment of chronic B cell leukemia: a case report]." Rinsho Ketsueki 30(10): 1876-80.





Hershberger, P. A., R. A. Modzelewski, et al. (1999). "1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo." Cancer Res 59(11): 2644-9.





Hershberger, P. A., W. D. Yu, et al. (2001). "Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis." Clin Cancer Res 7(4): 1043-51.





Higashimoto, Y., M. Ohata, et al. (1996). "1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line." Anticancer Res 16(5A): 2653-9.





Holick, M. F. (2003). "Vitamin D: A millenium perspective." J Cell Biochem 88(2): 296-307.





Hughes, A. M., B. K. Armstrong, et al. (2004). "Sun exposure may protect against non-Hodgkin lymphoma: a case-control study." Int J Cancer 112(5): 865-71.





Kizaki, M., A. W. Norman, et al. (1991). "1,25-Dihydroxyvitamin D3 receptor RNA: expression in hematopoietic cells." Blood 77(6): 1238-47.





Konety, B. R., J. P. Lavelle, et al. (2001). "Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo." J Urol 165(1): 253-8.





Majewski, S., M. Skopinska, et al. (1996). "Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis." J Investig Dermatol Symp Proc 1(1): 97-101.





Makishima, M., Y. Kanatani, et al. (1996). "Enhancement of activity of 1alpha, 25-dihydroxyvitamin D3 for growth inhibition and differentiation induction of human myelomonocytic leukemia cells by tretinoin tocoferil, an alpha-tocopherol ester of all-trans retinoic acid." Blood 87(8): 3384-94.





Mangelsdorf, D. J., C. Thummel, et al. (1995). "The nuclear receptor superfamily: the second decade." Cell 83(6): 835-9.





Manolagas, S. C., X. P. Yu, et al. (1994). "Vitamin D and the hematolymphopoietic tissue: a 1994 update." Semin Nephrol 14(2): 129-43.





Moffatt, K. A., W. U. Johannes, et al. (1999). "1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines." Clin Cancer Res 5(3): 695-703.





Naveilhan, P., F. Berger, et al. (1994). "Induction of glioma cell death by 1,25(OH)2 vitamin D3: towards an endocrine therapy of brain tumors?" J Neurosci Res 37(2): 271-7.





Peehl, D. M., R. J. Skowronski, et al. (1994). "Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells." Cancer Res 54(3): 805-10.





Puthier, D., R. Bataille, et al. (1996). "Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone." Blood 88(12): 4659-66.





Sardar, S., M. Chatterjee, et al. (1996). "Role of vitamin D3 on the activity patterns of hepatic drug metabolizing enzymes in transplantable murine lymphoma." Cancer Invest 14(4): 328-34.





Sarkar, A., B. K. Saha, et al. (2000). "Anticlastogenic potential of 1alpha,25-dihydroxyvitamin D3 in murine lymphoma." Cancer Lett 150(1): 1-13.





Shabahang, M., A. E. Buffan, et al. (1996). "The effect of 1, 25-dihydroxyvitamin D3 on the growth of soft-tissue sarcoma cells as mediated by the vitamin D receptor." Ann Surg Oncol 3(2): 144-9.





Takahashi, T., K. Nakamura, et al. (1997). "Differentiation of myeloid cells and 1,25-dihydroxyvitamin D3." Leuk Lymphoma 27(1-2): 25-33.





Zittermann, A. (2003). "Vitamin D in preventive medicine: are we ignoring the evidence?" Br J Nutr 89(5): 552-72.





Zugmaier, G., R. Jager, et al. (1996). "Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells." Br J Cancer 73(11): 1341-6.

 
 
 

PER LEGGERE E SCARICARE IL CAPITOLO SULLA VITAMINA D, COMPLETO DI BIBLIOGRAFIA E RELATIVI ABSTRACT, CLICCARE QUESTO LINK.
Il file è di 48 pagine in formato PDF e pesa 217 kb.


BIBLIOGRAFIA





Abe-Hashimoto, J., T. Kikuchi, et al. (1993). "Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen." Cancer Res 53(11): 2534-7.





Abe, E., C. Miyaura, et al. (1981). "Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3." Proc Natl Acad Sci U S A 78(8): 4990-4.





Beer, T. M. and A. Myrthue (2004). "Calcitriol in cancer treatment: from the lab to the clinic." Mol Cancer Ther 3(3): 373-81.





Beno, D. W., L. M. Brady, et al. (1995). "Protein kinase C and mitogen-activated protein kinase are required for 1,25-dihydroxyvitamin D3-stimulated Egr induction." J Biol Chem 270(8): 3642-7.





Berger, U., P. Wilson, et al. (1988). "Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues." J Clin Endocrinol Metab 67(3): 607-13.





Bernardi, R. J., C. S. Johnson, et al. (2002). "Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells." Endocrinology 143(7): 2508-14.





Bernardi, R. J., D. L. Trump, et al. (2001). "Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling." Clin Cancer Res 7(12): 4164-73.





Calvo, M. S., S. J. Whiting, et al. (2005). "Vitamin D intake: a global perspective of current status." J Nutr 135(2): 310-6.





Celli, A., C. Treves, et al. (1999). "Vitamin D receptor in SH-SY5Y human neuroblastoma cells and effect of 1,25-dihydroxyvitamin D3 on cellular proliferation." Neurochem Int 34(2): 117-24.





Colston, K., M. J. Colston, et al. (1981). "1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture." Endocrinology 108(3): 1083-6.





Colston, K. W., S. K. Chander, et al. (1992). "Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro." Biochem Pharmacol 44(4): 693-702.





Consolini, R., S. Pala, et al. (2001). "Effects of vitamin D on the growth of normal and malignant B-cell progenitors." Clin Exp Immunol 126(2): 214-9.





Cross, H. S., C. Huber, et al. (1991). "Antiproliferative effect of 1,25-dihydroxyvitamin D3 and its analogs on human colon adenocarcinoma cells (CaCo-2): influence of extracellular calcium." Biochem Biophys Res Commun 179(1): 57-62.





Cunningham, D., N. L. Gilchrist, et al. (1985). "Alfacalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas." Br Med J (Clin Res Ed) 291(6503): 1153-5.





French, L. E., A. A. Ramelet, et al. (1994). "Remission of cutaneous T-cell lymphoma with combined calcitriol and acitretin." Lancet 344(8923): 686-7.





Fujioka, T., M. Hasegawa, et al. (1998). "Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma." J Urol 160(1): 247-51.





Guyton, K. Z., T. W. Kensler, et al. (2003). "Vitamin D and vitamin D analogs as cancer chemopreventive agents." Nutr Rev 61(7): 227-38.





Guzey, M., C. Sattler, et al. (1998). "Combinational effects of vitamin D3 and retinoic acid (all trans and 9 cis) on proliferation, differentiation, and programmed cell death in two small cell lung carcinoma cell lines." Biochem Biophys Res Commun 249(3): 735-44.





Hara, K., K. Kusuzaki, et al. (2001). "Oral administration of 1 alpha hydroxyvitamin D3 inhibits tumor growth and metastasis of a murine osteosarcoma model." Anticancer Res 21(1A): 321-4.





Hashimoto, E., H. Takeuchi, et al. (1989). "[1 alpha(OH) D3 (Alfarol) is effective for the treatment of chronic B cell leukemia: a case report]." Rinsho Ketsueki 30(10): 1876-80.





Hershberger, P. A., R. A. Modzelewski, et al. (1999). "1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo." Cancer Res 59(11): 2644-9.





Hershberger, P. A., W. D. Yu, et al. (2001). "Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis." Clin Cancer Res 7(4): 1043-51.





Higashimoto, Y., M. Ohata, et al. (1996). "1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line." Anticancer Res 16(5A): 2653-9.





Holick, M. F. (2003). "Vitamin D: A millenium perspective." J Cell Biochem 88(2): 296-307.





Hughes, A. M., B. K. Armstrong, et al. (2004). "Sun exposure may protect against non-Hodgkin lymphoma: a case-control study." Int J Cancer 112(5): 865-71.





Kizaki, M., A. W. Norman, et al. (1991). "1,25-Dihydroxyvitamin D3 receptor RNA: expression in hematopoietic cells." Blood 77(6): 1238-47.





Konety, B. R., J. P. Lavelle, et al. (2001). "Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo." J Urol 165(1): 253-8.





Majewski, S., M. Skopinska, et al. (1996). "Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis." J Investig Dermatol Symp Proc 1(1): 97-101.





Makishima, M., Y. Kanatani, et al. (1996). "Enhancement of activity of 1alpha, 25-dihydroxyvitamin D3 for growth inhibition and differentiation induction of human myelomonocytic leukemia cells by tretinoin tocoferil, an alpha-tocopherol ester of all-trans retinoic acid." Blood 87(8): 3384-94.





Mangelsdorf, D. J., C. Thummel, et al. (1995). "The nuclear receptor superfamily: the second decade." Cell 83(6): 835-9.





Manolagas, S. C., X. P. Yu, et al. (1994). "Vitamin D and the hematolymphopoietic tissue: a 1994 update." Semin Nephrol 14(2): 129-43.





Moffatt, K. A., W. U. Johannes, et al. (1999). "1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines." Clin Cancer Res 5(3): 695-703.





Naveilhan, P., F. Berger, et al. (1994). "Induction of glioma cell death by 1,25(OH)2 vitamin D3: towards an endocrine therapy of brain tumors?" J Neurosci Res 37(2): 271-7.





Peehl, D. M., R. J. Skowronski, et al. (1994). "Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells." Cancer Res 54(3): 805-10.





Puthier, D., R. Bataille, et al. (1996). "Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone." Blood 88(12): 4659-66.





Sardar, S., M. Chatterjee, et al. (1996). "Role of vitamin D3 on the activity patterns of hepatic drug metabolizing enzymes in transplantable murine lymphoma." Cancer Invest 14(4): 328-34.





Sarkar, A., B. K. Saha, et al. (2000). "Anticlastogenic potential of 1alpha,25-dihydroxyvitamin D3 in murine lymphoma." Cancer Lett 150(1): 1-13.





Shabahang, M., A. E. Buffan, et al. (1996). "The effect of 1, 25-dihydroxyvitamin D3 on the growth of soft-tissue sarcoma cells as mediated by the vitamin D receptor." Ann Surg Oncol 3(2): 144-9.





Takahashi, T., K. Nakamura, et al. (1997). "Differentiation of myeloid cells and 1,25-dihydroxyvitamin D3." Leuk Lymphoma 27(1-2): 25-33.





Zittermann, A. (2003). "Vitamin D in preventive medicine: are we ignoring the evidence?" Br J Nutr 89(5): 552-72.





Zugmaier, G., R. Jager, et al. (1996). "Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells." Br J Cancer 73(11): 1341-6.

 
 
 

 

Documento Allegato

Stampa